Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-972P is a *processed pseudogene* derived from the U6 small nuclear RNA gene family. U6 snRNA is an essential and highly conserved component of the spliceosome, the multi-megadalton complex responsible for removing introns from pre-mRNA during splicing in the nucleus of eukaryotic cells[1][3]. However, RNU6-972P does not represent a functional copy; it is one of many genomic pseudogene variants originating from retrotransposition events mediated by long interspersed nuclear elements (LINE-1/L1)[4]. These pseudogenes are usually non-functional: they lack promoter activity, are typically not transcribed, and do not participate in physiological RNA splicing or other cellular processes[4][5]. They serve as genetic markers of retrotransposition in evolutionary genomics and do not act as therapeutic targets, nor are they implicated directly in disease or drug response. Key context: - The functional U6 snRNA is central to eukaryotic RNA splicing, catalyzing steps of intron removal, but pseudogene variants such as RNU6-972P lack this capacity and are considered inert genomic elements[1][3][4]. - There are hundreds of U6-related pseudogenes scattered throughout the human genome, all created by similar mechanisms and lacking biological function[4][5]. - The designation "pseudogene" explicitly means it is not an active or translatable gene. Summary of problems with this target: - RNU6-972P is not a drug target, receptor, enzyme, or transporter—it is an inactive, non-coding pseudogene[4]. - It is not associated with any known molecular function or disease state. - No drugs target this pseudogene, nor does it serve as a biomarker or safety concern. Relevant background: - The functional gene family, U6 snRNA, is critically important for splicing, but the pseudogenes are evolutionary by-products with no known cellular role[1][4]. - The presence of these pseudogenes is useful in population genetics and evolutionary biology but not in drug development or disease therapy contexts[4]. Correction for practical curation: - If searching for therapeutic or biological targets, use "U6 small nuclear RNA" or "snRNA U6" for the functional molecule, not the pseudogene records like RNU6-972P. - This specific entry is not appropriate as a drug discovery or biomarker target by current standards.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 972, pseudogene (RNU6-972P).